论文部分内容阅读
本期心血管病专刊以新型抗凝血药物、抗血小板药物等的临床合理应用为主题。抗凝治疗一直是血栓疾病的重要治疗手段,抗血小板药物治疗在急性冠状动脉综合征(ACS)的防治中非常重要。正如指南所推荐,双联抗血小板治疗仍然是ACS的一线药物治疗方案,但强化抗血小板治疗带来心血管获益的同时,由此引起的相关出血风险也是临床医生面对的常见而关注的问题。
The current issue of cardiovascular disease with new anticoagulant drugs, antiplatelet drugs, such as the clinical rational use of the theme. Anticoagulant therapy has been an important treatment for thrombotic diseases. Antiplatelet drug therapy is very important in the prevention and treatment of acute coronary syndrome (ACS). As recommended by the guidelines, dual antiplatelet therapy remains the first-line drug regimen for ACS, but the associated cardiovascular risk associated with enhanced antiplatelet therapy is also a common and clinical concern for clinicians problem.